Please upgrade your browser to make full use of twiends.   chrome   firefox   ie   safari  
Want to Grow Your Twitter Following, Free?
$PGNX..$5.39 solid continuation
$heff Bioturd definitions: "rising turd"; "floating turd"; & "sinking turd." More clarity this weekend on Bioturds. Can make money on all!
$ARWR..$12.60 on watch here.
$PGNX..$5.25 great move today.
$IBB down almost 1% to $264.29. Pullback has been needed. Creates opportunity for patient investors who weren't pouring $ in overbought mkt.
Market offering opportunity to select biotechs this a.m. & possibly tomorrow as well. Focus on solid near-term catalysts here (30-45 days).
$NPSP..$27.04 hit $26.69 earlier this morning. On watch here..
$NKTR..$13.22 pullback from $13.50 range past week.
$CNAT..$6.37 momentum slowed in this one for now. Will regain momentum in late December for 2015 push.
$AEZS..$1.28 pullback
$NAVB..$1.25 on watch. Busy Q4 on deck.
$CPRX..$2.39 here. Bounced from $2.20 level a few weeks ago and was lingering at $2.25 range the last week.
$SYN..$2.19 here. Closed yesterday at $2.35.
$THLD..$4.05 getting close to $4 level again. Shown to bounce here off this level. Mid-Sept data catalyst.
$SYN..$2.36 what a solid run. A few days ago this was at $1.80. Opened yesterday at $1.85.
US Department of Justice ends investigation of AstraZeneca drug trial by @cardiobrief
Retweeted by Sheff
RT @AnalystWire: Amicus Therapeutics $FOLD PT Raised to to $14 at Cowen on '012 Data
$FOLD..$5.36 was a good pre-mkt trade.
$NBY NovaBay announces primary, secondary endpoints not met in NVC-422 study. A small cap that has little to no institutional interest.
With Persistence And Phase 3 Win, Amicus Nears First Drug Approval… $FOLD #biotech
Retweeted by Sheff
$EXAS..$17.50 may look to revisit soon here.
$AVNR..$5.84 trading strong last few weeks. Two strong catalysts in Q4.
$PSDV..$4.87 trying to close in on $5.
$MNKD..$7.38 shorts been burned the last few trading days. Fun to watch this trade.
BioPharmCatalyst updates: $ASPX Phase 3 data due 4Q. $ONTY fails Phase 1/2 NSCLC trial.
Retweeted by Sheff